Combination therapeutics in complex diseases

Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target

(2015) Lisette P. Yco et al.   BMC CANCER

Updates on drug–target network; facilitating polypharmacology and data integration by growth of DrugBank database

(2015) Farnaz Barneh et al.   BRIEFINGS IN BIOINFORMATICS

Tetramethylpyrazine identified by a network pharmacology approach ameliorates methotrexate-induced oxidative organ injury

(2015) Bo Zhang et al.   JOURNAL OF ETHNOPHARMACOLOGY

A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin, and Concurrent Thoracic Radiation Therapy for Non–Small-Cell Lung Cancer: North Central Cancer Treatment Group (NCCTG)-N0321

(2015) Yujie Zhao et al.   Journal of Thoracic Oncology

Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study

(2015) Lawrence Blonde et al.   LANCET

Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)

(2015) Florian M Wagenlehner et al.   LANCET

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

(2015) Georgina V Long et al.   LANCET

Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group

(2015) Lieke H J Simkens et al.   LANCET

Prediction of drug gene associations via ontological profile similarity with application to drug repositioning

(2015) Maria Kissa et al.   METHODS

Mitigating risk in academic preclinical drug discovery

(2015) Jayme L. Dahlin et al.   NATURE REVIEWS DRUG DISCOVERY

Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

(2015) Sara M. Tolaney et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

(2015) A. Keith Stewart et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer

(2015) Sandra M. Swain et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Quantitative modeling of dose–response and drug combination based on pathway network

(2015) Jiangyong Gu et al.   Journal of Cheminformatics

A multi-label approach to target prediction taking ligand promiscuity into account

(2015) Avid M Afzal et al.   Journal of Cheminformatics

Combined Salvianolic Acid B and Ginsenoside Rg1 Exerts Cardioprotection against Ischemia/Reperfusion Injury in Rats

(2015) Yanping Deng et al.   PLoS One

A combination of eicosapentaenoic acid-free fatty acid, epigallocatechin-3-gallate and proanthocyanidins has a strong effect on mTOR signaling in colorectal cancer cells

(2014) Leonarda D’Angelo et al.   CARCINOGENESIS

Combination of the mTOR Inhibitor Ridaforolimus and the Anti-IGF1R Monoclonal Antibody Dalotuzumab: Preclinical Characterization and Phase I Clinical Trial

(2014) S. Di Cosimo et al.   CLINICAL CANCER RESEARCH

Multi-target approach for natural products in inflammation

(2014) Andreas Koeberle et al.   DRUG DISCOVERY TODAY

Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study

(2014) Thomas D Giles et al.   LANCET

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

(2014) Hansjochen Wilke et al.   LANCET ONCOLOGY

A community computational challenge to predict the activity of pairs of compounds

(2014) Mukesh Bansal et al.   NATURE BIOTECHNOLOGY

The genomic landscape of nasopharyngeal carcinoma

(2014) De-Chen Lin et al.   NATURE GENETICS

Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization

(2014) Dan E Arking et al.   NATURE GENETICS

Genome-wide trans-ancestry meta-analysis provides insight into the genetic architecture of type 2 diabetes susceptibility

(2014) Anubha Mahajan et al.   NATURE GENETICS

Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

(2014) Luca Richeldi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Thyroid Hormone Inactivation in Gastrointestinal Stromal Tumors

(2014) Michelle A. Maynard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Albumin-Bound Paclitaxel plus Gemcitabine in Pancreatic Cancer

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

(2014) Lotfi Benboubker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

(2014) Valentin Goede et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer

(2014) Fotios Loupakis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Prediction of resistance development against drug combinations by collateral responses to component drugs

(2014) C. Munck et al.   Science Translational Medicine

Knowledge-based Fragment Binding Prediction

(2014) Grace W. Tang et al.   PLoS Computational Biology

Similarity-based machine learning methods for predicting drug–target interactions: a brief review

(2013) Hao Ding et al.   BRIEFINGS IN BIOINFORMATICS

Network-Based Approaches in Drug Discovery and Early Development

(2013) J M Harrold et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Bone morphogenetic protein 4 promotes mammalian oogonial stem cell differentiation via Smad1/5/8 signaling

(2013) Eun-Sil Park et al.   FERTILITY AND STERILITY

Reduced hepatotoxicity by total glucosides of paeony in combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis

(2013) Zhu Chen et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Training Based on Ligand Efficiency Improves Prediction of Bioactivities of Ligands and Drug Target Proteins in a Machine Learning Approach

(2013) Nobuyoshi Sugaya   Journal of Chemical Information and Modeling

Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial

(2013) Andrew Howman et al.   LANCET

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

(2013) David Cunningham et al.   LANCET

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial

(2013) Josef S Smolen et al.   LANCET

Genetics of rheumatoid arthritis contributes to biology and drug discovery

(2013) Yukinori Okada et al.   NATURE

A community-driven global reconstruction of human metabolism

(2013) Ines Thiele et al.   NATURE BIOTECHNOLOGY

WNT signaling in bone homeostasis and disease: from human mutations to treatments

(2013) Roland Baron et al.   NATURE MEDICINE

Pancreatic Atrophy — A New Late Toxic Effect of Sorafenib

(2013) Ségolène Hescot et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

(2013) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Predicting Drug-Target Interactions Using Drug-Drug Interactions

(2013) Shinhyuk Kim et al.   PLoS One

High-Throughput Methods for Combinatorial Drug Discovery

(2013) X. Sun et al.   Science Translational Medicine

A Network Inference Method for Large-Scale Unsupervised Identification of Novel Drug-Drug Interactions

(2013) Roger Guimerà et al.   PLoS Computational Biology

Network-based drug discovery by integrating systems biology and computational technologies

(2012) E. L. Leung et al.   BRIEFINGS IN BIOINFORMATICS

A series of case studies: practical methodology for identifying antinociceptive multi-target drugs

(2012) Min-Hee Pang et al.   DRUG DISCOVERY TODAY

Passenger deletions generate therapeutic vulnerabilities in cancer

(2012) Florian L. Muller et al.   NATURE

Architecture of the human regulatory network derived from ENCODE data

(2012) Mark B. Gerstein et al.   NATURE

Diagnosing the decline in pharmaceutical R&D efficiency

(2012) Jack W. Scannell et al.   NATURE REVIEWS DRUG DISCOVERY

Intra-axonal Translation of SMAD1/5/8 Mediates Retrograde Regulation of Trigeminal Ganglia Subtype Specification

(2012) Sheng-Jian Ji et al.   NEURON

Three in one: safety, efficacy, and patient acceptability of triple fixed-dose combination medicine in the management of hypertension

(2012) Addison Taylor et al.   Patient Preference and Adherence

The rise and fall of supervised machine learning techniques

(2011) L. J. Jensen et al.   BIOINFORMATICS

Heart Disease and Stroke Statistics—2012 Update

(2011) et al.   CIRCULATION

Biosimilars of Biological Drug Therapies

(2011) George Dranitsaris et al.   DRUGS

The genetics of asthma and allergic disease: a 21st century perspective

(2011) Carole Ober et al.   IMMUNOLOGICAL REVIEWS

Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes

(2011) Thomas Force et al.   NATURE REVIEWS DRUG DISCOVERY

Combination Drugs — Hype, Harm, and Hope

(2011) Scott H. Podolsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib

(2011) Vince D. Cataldo et al.   NEW ENGLAND JOURNAL OF MEDICINE

The translatability of animal models for clinical development: biomarkers and disease models

(2010) Alexandra Wendler et al.   CURRENT OPINION IN PHARMACOLOGY

Optimal Drug Synergy in Antimicrobial Treatments

(2010) Joseph Peter Torella et al.   PLoS Computational Biology

Combination therapy: Opportunities and challenges for polymer–drug conjugates as anticancer nanomedicines

(2009) Francesca Greco et al.   ADVANCED DRUG DELIVERY REVIEWS

A chemogenomics view on protein-ligand spaces

(2009) Helena Strömbergsson et al.   BMC BIOINFORMATICS

BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation

(2009) K. N. Retting et al.   DEVELOPMENT

Escape from Flatland: Increasing Saturation as an Approach to Improving Clinical Success

(2009) Frank Lovering et al.   JOURNAL OF MEDICINAL CHEMISTRY

Developing and validating predictive decision tree models from mining chemical structural fingerprints and high–throughput screening data in PubChem

(2008) Lianyi Han et al.   BMC BIOINFORMATICS

Ligand-Target Prediction Using Winnow and Naive Bayesian Algorithms and the Implications of Overall Performance Statistics

(2008) Florian Nigsch et al.   Journal of Chemical Information and Modeling

Network pharmacology: the next paradigm in drug discovery

(2008) Andrew L Hopkins   Nature Chemical Biology

Dimorphic effects of Notch signaling in bone homeostasis

(2008) Feyza Engin et al.   NATURE MEDICINE

Accelerated evolution of resistance in multidrug environments

(2008) M. Hegreness et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Drug interactions modulate the potential for evolution of resistance

(2008) J.-B. Michel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA